In this special report, the editors Med Ad News have compiled lists that present the drugs in development for the world’s top 50 pharmaceutical companies.
The lists provide the product name, the chemical or substance composition of the product, the indication as intended for the product while it is in clinical development, the status of the product, and the division of the company that is developing the product and intends to market the product and/or the name of the partner company.
All phases of development have been considered for this special report — preclinical development, Phase I, Phase II, Phase III, and awaiting approval.All regions of the world have been considered, with particular emphasis placed on the United States, the European Union, and Japan.
Data in this special report have been up-dated through September 2004. In addition to the pipelines, the editors have provided a table on page 3 that shows how much the pharmaceutical companies spent on research and development in 2003. The data come from a database maintained by Engel Publishing Partners, the publisher of Med Ad News and the developer of PharmaLive.com.